420 related articles for article (PubMed ID: 20189842)
21. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
[TBL] [Abstract][Full Text] [Related]
22. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
24. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
25. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
26. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
[TBL] [Abstract][Full Text] [Related]
28. Presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND.
Inci K; Dogan HS; Akdogan B; Baydar DE; Ergen A; Ozen H
Urol Oncol; 2011; 29(1):38-42. PubMed ID: 19269199
[TBL] [Abstract][Full Text] [Related]
29. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
[TBL] [Abstract][Full Text] [Related]
30. Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection.
Liu NW; Cary C; Strine AC; Beck SD; Masterson TA; Bihrle R; Foster RS
Urology; 2015 Nov; 86(5):981-4. PubMed ID: 26232690
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
[TBL] [Abstract][Full Text] [Related]
32. [Nerve-sparing retroperitoneal lymph node dissection for stage IIA testicular embryonal carcinoma: a case report].
Terachi T; Arai Y; Maeda S; Takeuchi H; Yoshida O
Hinyokika Kiyo; 1992 Oct; 38(10):1191-4. PubMed ID: 1481782
[TBL] [Abstract][Full Text] [Related]
33. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J
Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079
[TBL] [Abstract][Full Text] [Related]
34. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
[TBL] [Abstract][Full Text] [Related]
35. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
Ehrlich Y; Yossepowitch O; Kedar D; Baniel J
BJU Int; 2006 Jun; 97(6):1221-4. PubMed ID: 16686715
[TBL] [Abstract][Full Text] [Related]
36. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
[TBL] [Abstract][Full Text] [Related]
37. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
38. Retroperitoneal vascular surgery for the treatment of giant growing teratoma syndrome.
Stella M; Gandini A; Meeus P; Aleksic I; Flechon A; Cropet C; Droz JP; Rivoire M
Urology; 2012 Feb; 79(2):365-70. PubMed ID: 22173179
[TBL] [Abstract][Full Text] [Related]
39. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
Heidenreich A; Pfister D; Witthuhn R; Thüer D; Albers P
Eur Urol; 2009 Jan; 55(1):217-24. PubMed ID: 18926622
[TBL] [Abstract][Full Text] [Related]
40. Retroperitoneal lymph node dissection (RPLND) post chemotherapy for non-seminomatous testicular neoplasms: what is the significance of residual masses at scanner control after chemotherapy and should they be removed?
Solé-Balcells F; Villavicencio H; Germá R
Prog Clin Biol Res; 1989; 303():759-62. PubMed ID: 2780671
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
